135 related articles for article (PubMed ID: 28789809)
1. Preclinical validation of
Huizing FJ; Hoeben BAW; Franssen G; Lok J; Heskamp S; Oosterwijk E; Boerman OC; Bussink J
Radiother Oncol; 2017 Sep; 124(3):521-525. PubMed ID: 28789809
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
[TBL] [Abstract][Full Text] [Related]
3. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
4. CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models.
Huizing FJ; Garousi J; Lok J; Franssen G; Hoeben BAW; Frejd FY; Boerman OC; Bussink J; Tolmachev V; Heskamp S
Sci Rep; 2019 Dec; 9(1):18898. PubMed ID: 31827111
[TBL] [Abstract][Full Text] [Related]
5. Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models.
Huizing FJ; Hoeben BAW; Lok J; Boerman OC; Heskamp S; Bussink J
Phys Imaging Radiat Oncol; 2021 Jul; 19():145-150. PubMed ID: 34485720
[TBL] [Abstract][Full Text] [Related]
6. Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells.
van Lith SAM; Huizing FJ; Franssen GM; Hoeben BAW; Lok J; Doulkeridou S; Boerman OC; Gotthardt M; van Bergen En Henegouwen PMP; Bussink J; Heskamp S
Mol Pharm; 2022 Oct; 19(10):3511-3520. PubMed ID: 35044182
[TBL] [Abstract][Full Text] [Related]
7. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
[TBL] [Abstract][Full Text] [Related]
8. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
9. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
10. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
11. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines.
Troost EG; Bussink J; Kaanders JH; van Eerd J; Peters JP; Rijken PF; Boerman OC; van der Kogel AJ
Radiother Oncol; 2005 Aug; 76(2):194-9. PubMed ID: 16024110
[TBL] [Abstract][Full Text] [Related]
13. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
14. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
Carlin S; Khan N; Ku T; Longo VA; Larson SM; Smith-Jones PM
PLoS One; 2010 May; 5(5):e10857. PubMed ID: 20523727
[TBL] [Abstract][Full Text] [Related]
16. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
17. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: correlation between primary and xenograft tumors.
Stegeman H; Rademakers SE; Span PN; Takes RP; van der Kogel AJ; Kaanders JH; Bussink J
Head Neck; 2014 Sep; 36(9):1288-95. PubMed ID: 24668936
[TBL] [Abstract][Full Text] [Related]
19. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
